{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=14", "query": { "intervention": "fludarabine", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1451, "total_pages": 146, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T09:42:04.737Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03524235", "title": "Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "CLL", "Chronic Lymphocytic Leukemia", "Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Haploidentical Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "CD56-Enriched Donor Lymphocyte Infusion", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Noah Merin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2018-07-18", "completion_date": "2024-11-06", "has_results": false, "last_update_posted_date": "2024-11-12", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03524235" }, { "nct_id": "NCT00923390", "title": "Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cancer", "Kidney Cancer" ], "interventions": [ { "name": "2G-1 TCR Retroviral Vector-Transduced lyn", "type": "GENETIC" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 5, "start_date": "2009-03-02", "completion_date": "2012-08-24", "has_results": false, "last_update_posted_date": "2019-04-09", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923390" }, { "nct_id": "NCT01105650", "title": "Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "Breast Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Natural killer cells", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2010-07", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01105650" }, { "nct_id": "NCT02858310", "title": "E7 TCR T Cells for Human Papillomavirus-Associated Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Papillomavirus Infections", "Cervical Intraepithelial Neoplasia", "Carcinoma In Situ", "Vulvar Neoplasms", "Vulvar Diseases" ], "interventions": [ { "name": "E7 TCR cells", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Chest CT and MRI or PET", "type": "DIAGNOSTIC_TEST" }, { "name": "PFT", "type": "DIAGNOSTIC_TEST" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Droperidol", "type": "DRUG" }, { "name": "Prochlorperazine", "type": "DRUG" }, { "name": "Diphenoxylate HCL", "type": "DRUG" }, { "name": "Atropine sulfate", "type": "DRUG" }, { "name": "Codeine sulfate", "type": "DRUG" }, { "name": "Loperamide", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine HCL", "type": "DRUG" }, { "name": "Hydroxyzine HCL", "type": "DRUG" }, { "name": "Meperidine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 224, "start_date": "2017-01-27", "completion_date": "2025-07-02", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 2, "location_summary": "Bethesda, Maryland • New Brunswick, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02858310" }, { "nct_id": "NCT01010217", "title": "Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Blood Stem Cell Transplant Failure", "Leukemia", "Hematologic Malignancies" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycofenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 176, "start_date": "2009-11-05", "completion_date": "2017-10-05", "has_results": true, "last_update_posted_date": "2020-03-25", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01010217" }, { "nct_id": "NCT00801060", "title": "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Lumiliximab + FCR", "type": "DRUG" }, { "name": "FCR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2008-02", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2015-10-02", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 9, "location_summary": "Gainesville, Florida • Miami, Florida • Chicago, Illinois + 5 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00801060" }, { "nct_id": "NCT07825389", "title": "C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Sclerosis", "Primary Progressive Multiple Sclerosis", "Secondary Progress Multiple Sclerosis (SPMS)", "Primary Progressive Multiple Sclerosis (PPMS)", "MS", "MS (Multiple Sclerosis)", "Neuro-Degenerative Disease", "Neuro-Degenerative Diseases", "Autoimmune" ], "interventions": [ { "name": "C-CAR168", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbelZeta Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 119, "start_date": "2027-02", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 2, "location_summary": "Gilbert, Arizona • La Jolla, California", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07825389" }, { "nct_id": "NCT00346359", "title": "Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 40, "start_date": "2006-03", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2010-05-14", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00346359" }, { "nct_id": "NCT00183989", "title": "Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Fludarabine, Mitoxantrone and Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2000-08", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00183989" }, { "nct_id": "NCT02660281", "title": "URMC Related Haplo-identical Donor BMT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematological Disease", "Immune Deficiencies", "Solid Tumors", "Myelofibrosis", "Multiple Myeloma", "Lymphoma" ], "interventions": [ { "name": "Total Body Irradiation 1200 cGy", "type": "RADIATION" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Pre-Stem Cell Infusion Cyclophosphamide", "type": "DRUG" }, { "name": "Pre-Stem Cell Infusion Mesna", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Infusion", "type": "PROCEDURE" }, { "name": "Post-Stem Cell Infusion Cyclophosphamide", "type": "DRUG" }, { "name": "Post-Stem Cell Infusion Mesna", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "75 Years", "sex": "ALL", "summary": "6 Months to 75 Years" }, "enrollment_count": 74, "start_date": "2015-10", "completion_date": "2021-01-07", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-10-25T09:42:04.737Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02660281" } ] }